ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) and iSpecimen (NASDAQ:ISPC – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares ProMIS Neurosciences and iSpecimen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

4.2% of iSpecimen shares are held by institutional investors. 32.3% of iSpecimen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

iSpecimen has higher revenue and earnings than ProMIS Neurosciences.

Analyst Recommendations

This is a breakdown of current recommendations for ProMIS Neurosciences and iSpecimen, as provided by MarketBeat.

iSpecimen has a consensus price target of $7.63, suggesting a potential upside of 403.30%. Given iSpecimen's higher probable upside, analysts clearly believe iSpecimen is more favorable than ProMIS Neurosciences.

Volatility & Risk

ProMIS Neurosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, iSpecimen has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Summary

iSpecimen beats ProMIS Neurosciences on 9 of the 11 factors compared between the two stocks.

About ProMIS Neurosciences

(Get Rating)

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

About iSpecimen

(Get Rating)

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.